DEVELOPMENT OF NANOCARRIER SYSTEM FOR INHALER CHEMOTHERAPY, CHARACTERIZATION AND IN VITRO STUDIES
Project no. 20099 · Status: Kapanmış · 2017
Summary
Lung cancer is the most frequently occured cancer type and causes 23% of total cancer related death in worlwide. Pulmonary drug delivery for lung cancer therapy provides local enhanced drug concentration, descreased required drug dose and eventually decraesed systemic side effects. Doxorubicin is widely used for treatment of many cancer types such as breast, ovarian and lung cancer. In this study, it was aimed that development of inhalable doxorubicin carrying nanoparticular system. Alginate and chitosan which have mucoadhesive properties were used as biopolymers for nanoparticle synthesis. Alginate/chitosan nanoparticles were prepared and bound with doxorubicin via PEGdiacid spacer with amide bond. FTIR, zetasizer and SEM analyses were perfomed in all steps and then in vitro drug release and cytotoxicity tests were carried out. It was found that doxorubicin carrying nanoparticles had 0.44 mg drug in per mg nanoparticle, hydrodynamic size as 217.23 nm±15.00, zeta potential as -25.17 mV±2.67 and more drug release rate in acidic medium than that of physiological medium. In addition nanoparticles had cytotoxicity against A549-luc-C8 lung cancer cells. According to all data, it is thought that doxorubicin bound alginate/chitosan nanoparticles could have potential for treatment of lung cancer through inhaler route.